Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13764880 | 0.81 | GAA (0.51) | GAANPY5RNPY2R | |
| SCHEMBL3999333 | 0.79 | GAA (0.45) | GAANPY5RNPY2R | |
| SCHEMBL4006717 | 0.78 | GAA (0.46) | GAANPY5RNPY2R | |
| SCHEMBL13764895 | 0.78 | GAA (0.46) | GAANPY5RNPY2R | |
| SCHEMBL3999508 | 0.78 | KLK7 (0.37) | SLC6A3 | |
| SCHEMBL13769307 | 0.77 | GAA (0.56) | GAANPY5RNPY2R | |
| SCHEMBL13764896 | 0.77 | GAA (0.46) | GAANPY5RNPY2R | |
| SCHEMBL4005444 | 0.77 | GAA (0.46) | GAANPY5RNPY2R | |
| SCHEMBL13764897 | 0.75 | NPY5R (0.39) | GAANPY5RNPY2R | |
| SCHEMBL13764906 | 0.70 | GAA (0.55) | GAANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563888-B2 | Process for the preparation of diphenyl azetidinone derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7563888-B2 | Process for the preparation of diphenyl azetidinone derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-20070149501-A1 | PROCESS FOR THE PREPARATION OF DIPHENYL AZETIDINONE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149501-A1 | PROCESS FOR THE PREPARATION OF DIPHENYL AZETIDINONE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| EP-1753717-A1 | METHOD FOR PRODUCING DIPHENYL AZETIDINONE DERIVATIVES | Sanofi-Aventis Deutschland GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005113495-A1 | METHOD FOR PRODUCING DIPHENYL AZETIDINONE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149501-A1 | PROCESS FOR THE PREPARATION OF DIPHENYL AZETIDINONE DERIVATIVES | CYP46A1, APOB, DHCR7 | GAA 1290/4885NPY5R 714/4885CCR5 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.